C. Andre

Results of a Phase II Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3- to 25-Year-Old Spinal Muscular Atrophy Patients

E. Bertini, M. Walter, U. Schara, 2014 .

Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma

B. Neyns, B. Filleul, V. Verschaeve, 2015, Journal of Neurology.

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma

I. Salmon, B. Neyns, A. Michotte, 2017, Journal of Neuro-Oncology.

G.O.19 Results of a phase II study to assess safety and efficacy of olesoxime (TRO19622) in 3–25 years old spinal muscular atrophy patients

E. Mercuri, F. Muntoni, F. Rivier, 2014, Neuromuscular Disorders.

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma

A. Michotte, V. Verschaeve, M. Mercier, 2017, Journal of Neuro-Oncology.